Weller M, Laing W
Biochim Biophys Acta. 1979 Mar 8;551(2):406-19. doi: 10.1016/0005-2736(89)90016-3.
In the absence of cyclic nucleotides heart microsomes have two classes of calcium binding sites with binding constants of 0.69 and 0.071 micron-1 and capacities of 2.2 and 9.7 nmol/mg protein, respectively. Neither cyclic AMP nor monobutyryl cyclic AMP affect binding but cyclic GMP and monobutyryl cyclic GMP cause the complete loss of the high affinity calcium binding sites, Cyclic GMP (but not monobutyryl cyclic GMP) also causes a decrease in the binding constant of the low affinity binding sites. AMP, GMP and Tris-butyrate do not affect calcium binding. The effects of the cyclic nucleotides are direct and are not mediated by protein phosphorylation. Phosphorylation of microsomal proteins increases the binding constant but not the capacity of the high affinity calcium binding sites. The capacity and also, perhaps, binding constant of the low affinity sites is also increased by phosphorylation. In additon to their effects on calcium binding the cyclic nucleotides also affect the movements of calcium into and out of the microsomes. The effects are again direct and not mediated by protein phosphorylation. Cyclic GMP decreases the rate of Ca2+ efflux from preloaded cardiac microsomes and also appears to decrease the rate of uptake of Ca2+ by cardiac microsomes though this effect is less clear cut than the action on efflux. The cyclic nucleotide has a half maximal effect at a concentration of 100 microns. By contrast cyclic AMP increases the rate of influx of Ca2+ into heart microsomes and the rate of efflux of Ca2+ from preloaded preparations. The effect is, however, rather slight. It is suggested that the most obvious interpretation of these results is that cyclic GMP decreases the Ca2+ permeability of the cardiac microsomal membrane while cyclic AMP increases the permeability. In contrast to the results found with membrane preparations from certain other tissues phosphorylation of cardiac microsomal proteins does not appear to alter Ca2+ efflux or influx out of, or into, cardiac microsomal preparations. It is thus concluded that phosphorylation of cardiac microsomal proteins does not affect the Ca2+ permeability of the microsomal membrane.
在缺乏环核苷酸的情况下,心脏微粒体有两类钙结合位点,结合常数分别为0.69和0.071μmol⁻¹,结合容量分别为2.2和9.7nmol/mg蛋白质。环磷酸腺苷(cAMP)和单丁酰环磷酸腺苷(mBcAMP)均不影响结合,但环磷酸鸟苷(cGMP)和单丁酰环磷酸鸟苷(mBcGMP)会导致高亲和力钙结合位点完全丧失。环磷酸鸟苷(而非单丁酰环磷酸鸟苷)还会导致低亲和力结合位点的结合常数降低。腺苷酸(AMP)、鸟苷酸(GMP)和三丁酸盐不影响钙结合。环核苷酸的作用是直接的,并非由蛋白质磷酸化介导。微粒体蛋白的磷酸化增加了高亲和力钙结合位点的结合常数,但不增加其结合容量。低亲和力位点的结合容量以及可能的结合常数也因磷酸化而增加。除了对钙结合的影响外,环核苷酸还影响钙进出微粒体的转运。这些作用同样是直接的,并非由蛋白质磷酸化介导。环磷酸鸟苷降低了预加载的心脏微粒体中Ca²⁺的外流速率,并且似乎也降低了心脏微粒体对Ca²⁺的摄取速率,尽管这种作用比对外流的作用更不明确。环核苷酸在浓度为100μmol时产生半数最大效应。相比之下,环磷酸腺苷增加了Ca²⁺流入心脏微粒体的速率以及预加载制剂中Ca²⁺的外流速率。然而,这种作用相当轻微。有人认为,对这些结果最明显的解释是,环磷酸鸟苷降低了心脏微粒体膜的Ca²⁺通透性,而环磷酸腺苷增加了通透性。与从某些其他组织制备的膜所得到的结果不同,心脏微粒体蛋白的磷酸化似乎并未改变Ca²⁺从心脏微粒体制剂中外流或流入的情况。因此得出结论,心脏微粒体蛋白的磷酸化不影响微粒体膜的Ca²⁺通透性。